Phenotypic Differences Among Familial Partial Lipodystrophy Due to LMNA or PPARG Variants

被引:18
|
作者
Vasandani, Chandna [1 ,2 ]
Li, Xilong [3 ]
Sekizkardes, Hilal [4 ]
Brown, Rebecca J. [5 ]
Garg, Abhimanyu [1 ,2 ,6 ,7 ]
机构
[1] UT Southwestern Med Ctr Dallas, Div Nutr & Metab Dis, Dallas, TX 75390 USA
[2] UT Southwestern Med Ctr Dallas, Ctr Human Nutr, Dept Internal Med, Dallas, TX 75390 USA
[3] UT Southwestern Med Ctr Dallas, Dept Populat & Data Sci, Dallas, TX 75390 USA
[4] Natl Inst Child Hlth & Human Dev, NIH, Bethesda, MD 20892 USA
[5] Natl Inst Diabet & Digest & Kidney Dis, NIH, Bethesda, MD 20892 USA
[6] Dept Internal Med, Div Nutr & Metab Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
[7] Ctr Human Nutr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
基金
美国国家卫生研究院;
关键词
PPARG; LMNA; familial partial lipodystrophy; dual-energy X-ray absorptiometry; triglycerides; diabetes mellitus; ENCODING LAMIN A/C; INSULIN-RESISTANCE; MISSENSE MUTATIONS; DUNNIGAN VARIETY; POSTMORTEM FINDINGS; GAMMA; FAT; ABNORMALITIES; COMPLICATIONS; PREVALENCE;
D O I
10.1210/jendso/bvac155
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Despite several reports of familial partial lipodystrophy (FPLD) type 2 (FPLD2) due to heterozygous LMNA variants and FPLD3 due to PPARG variants, the phenotypic differences among them remain unclear. Objective To compare the body fat distribution, metabolic parameters, and prevalence of metabolic complications between FPLD3 and FPLD2. Methods A retrospective, cross-sectional comparison of patients from 2 tertiary referral centers-UT Southwestern Medical Center and the National Institute of Diabetes and Digestive and Kidney Diseases. A total of 196 females and 59 males with FPLD2 (age 2-86 years) and 28 females and 4 males with FPLD3 (age 9-72 years) were included. The main outcome measures were skinfold thickness, regional body fat by dual-energy X-ray absorptiometry (DXA), metabolic variables, and prevalence of diabetes mellitus and hypertriglyceridemia. Results Compared with subjects with FPLD2, subjects with FPLD3 had significantly increased prevalence of hypertriglyceridemia (66% vs 84%) and diabetes (44% vs 72%); and had higher median fasting serum triglycerides (208 vs 255 mg/dL), and mean hemoglobin A1c (6.4% vs 7.5%). Compared with subjects with FPLD2, subjects with FPLD3 also had significantly higher mean upper limb fat (21% vs 27%) and lower limb fat (16% vs 21%) on DXA and increased median skinfold thickness at the anterior thigh (5.8 vs 11.3 mm), calf (4 vs 6 mm), triceps (5.5 vs 7.5 mm), and biceps (4.3 vs 6.8 mm). Conclusion Compared with subjects with FPLD2, subjects with FPLD3 have milder lipodystrophy but develop more severe metabolic complications, suggesting that the remaining adipose tissue in subjects with FPLD3 may be dysfunctional or those with mild metabolic disease are underrecognized.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants
    Sekizkardes, Hilal
    Cochran, Elaine
    Malandrino, Noemi
    Garg, Abhimanyu
    Brown, Rebecca J.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (08): : 3068 - 3076
  • [2] Podocytopathies associated with familial partial lipodystrophy due to LMNA variants: report of two cases
    Morguetti, Maria Julia
    Neves, Precil Diego Miranda de Menezes
    Korkes, Ilana
    Padilha, Wallace Stwart Carvalho
    Jorge, Lecticia Barbosa
    Watanabe, Andreia
    Watanabe, Elieser Hitoshi
    Malheiros, Denise Maria Avancini Costa
    Noronha, Irene de Lourdes
    Dib, Sergio Atala
    Onuchic, Luiz Fernando
    Moises, Regina S.
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2024, 68
  • [3] Myopathy in patients with familial partial lipodystrophy due to LMNA mutations
    Spuler, S
    Kalbhenn, T
    Schmidt, HJ
    NEUROMUSCULAR DISORDERS, 2004, 14 (8-9) : 591 - 591
  • [4] A case of familial partial lipodystrophy due to a rare homozygous LMNA mutation
    De Buitleir, Ciara
    Newman, Christine
    Griffin, Tomas
    O'Shea, Paula
    O'Brien, Timothy
    Liew, Aaron
    Dinneen, Sean
    IRISH JOURNAL OF MEDICAL SCIENCE, 2024, 193 : S180 - S180
  • [5] Familial partial lipodystrophy with gene mutation in both LMNA and PPARG: report of a case and review of literature
    Zhou, Guiming
    Wang, Yang
    Xu, Mei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (12): : 13027 - 13031
  • [6] ADIPOCYTE DYSFUNCTION IN AN IPSC MODEL OF FAMILIAL PARTIAL LIPODYSTROPHY DUE TO MUTATIONS IN LMNA
    Alvarez, Aluet Borrego
    Liu, Katie
    Gobble, McKinlee
    Grupe, Michael
    Buchser, William
    Baldridge, Dustin
    Stone, Stephen
    HORMONE RESEARCH IN PAEDIATRICS, 2024, 97 : 154 - 155
  • [7] Response to treatment with rosiglitazone in familial partial lipodystrophy due to a mutation in the LMNA gene
    Owen, KR
    Donohoe, M
    Ellard, S
    Hattersley, AT
    DIABETIC MEDICINE, 2003, 20 (10) : 823 - 827
  • [8] Cardiac laminopathy in familial partial lipodystrophy type 2 secondary to variants in the LMNA gene
    Moreno Tirado, Antonio
    Rodriguez Ortega, Pilar
    Calle Isorna, Jose Maria
    MEDICINA CLINICA, 2024, 163 (12): : 634 - 635
  • [9] Cosegregation of Focal Segmental Glomerulosclerosis in a Family with Familial Partial Lipodystrophy due to a Mutation in LMNA
    Thong, Kah Mean
    Xu, Yaoxian
    Cook, Jackie
    Takou, Anna
    Wagner, Bart
    Kawar, Bisher
    Ong, Albert C. M.
    NEPHRON CLINICAL PRACTICE, 2013, 124 (1-2): : 31 - 37
  • [10] Familial partial lipodystrophy type 3: a new mutation on the PPARG gene
    Eva Lau
    Davide Carvalho
    Joana Oliveira
    Susana Fernandes
    Paula Freitas
    Hormones, 2015, 14 (2) : 317 - 320